ALK and non-small cell lung carcinoma: However, patient populations with NSCLC tumors driven by EGFR mutations or EML4-ALK translocations treated with PD-1/PD-L1 inhibitors showed reduced ORRs compared to patient populations harboring EGFR and ALK wild-type tumors.